Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) EBIT (2016 - 2025)

Neurocrine Biosciences' EBIT history spans 16 years, with the latest figure at $210.9 million for Q4 2025.

  • For Q4 2025, EBIT rose 48.52% year-over-year to $210.9 million; the TTM value through Dec 2025 reached $619.1 million, up 8.52%, while the annual FY2025 figure was $619.1 million, 8.52% up from the prior year.
  • EBIT reached $210.9 million in Q4 2025 per NBIX's latest filing, down from $239.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $239.0 million in Q3 2025 to a low of -$114.2 million in Q1 2023.
  • Average EBIT over 5 years is $89.6 million, with a median of $93.6 million recorded in 2022.
  • Peak YoY movement for EBIT: surged 384.85% in 2022, then crashed 3783.87% in 2023.
  • A 5-year view of EBIT shows it stood at -$36.3 million in 2021, then soared by 384.85% to $103.4 million in 2022, then surged by 45.36% to $150.3 million in 2023, then decreased by 5.52% to $142.0 million in 2024, then surged by 48.52% to $210.9 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's EBIT are $210.9 million (Q4 2025), $239.0 million (Q3 2025), and $145.6 million (Q2 2025).